title: [Rituximab-induced acute thrombocytopenia in a patient with chronic lymphocytic leukemia].
abstract: BACKGROUND
  Rituximab is a chimeric anti-CD20 monoclonal antibody generally well tolerated. However, a severe but rare rituximab-related immune-toxic syndrome, associating fever, chills and thrombocytopenia can occur shortly after the infusion.
  
  
  METHODS
  We report a case of severe acute rituximab-induced thrombocytopenia with favorable outcome in a patient with chronic lymphocytic leukemia and discuss the possible underlying mechanisms.
  
  
  CONCLUSIONS
  Despite the potential initial severity of rituximab-induced thrombocytopenia in CLL, chemotherapy should not be discontinued; tolerance might increase as the hematologic disorder is controlled.
authors.affiliation: Service de néphrologie, hôpital La-Conception, Assistance publique-Hôpitaux de Marseille, Aix-Marseille université, 147, boulevard Baille, 13005 Marseille, France. Electronic address: mickael.bobot@ap-hm.fr.
authors.forename: M
authors.initials: M
authors.lastname: Bobot
authors.affiliation: Service de dermatologie, hôpital Nord, Assistance publique-Hôpitaux de Marseille, Aix-Marseille université, chemin des Bourrely, 13015 Marseille, France.
authors.forename: M
authors.initials: M
authors.lastname: Benzaquen
authors.affiliation: Service de pharmacologie clinique et pharmacovigilance, centre régional de pharmacovigilance Marseille Provence Corse, hôpital Sainte-Marguerite, AP-HM, 270, boulevard de Sainte-Marguerite, 13009 Marseille, France.
authors.forename: F
authors.initials: F
authors.lastname: Rouby
authors.affiliation: Département de médecine interne, service de médecine interne générale, HUG, 4, rue Gabrielle-Perret-Gentil, 1211 Genève 14, Suisse.
authors.forename: D
authors.initials: D
authors.lastname: Lebowitz
authors.affiliation: Département de médecine interne, service de médecine interne générale, HUG, 4, rue Gabrielle-Perret-Gentil, 1211 Genève 14, Suisse.
authors.forename: J
authors.initials: J
authors.lastname: Serratrice
authors.affiliation: Service de médecine interne, hôpital La Timone, Assistance publique-Hôpitaux de Marseille, Aix-Marseille université, 264, rue Saint-Pierre, 13005 Marseille, France.
authors.forename: J-M
authors.initials: JM
authors.lastname: Durand
mesh_terms: D000208:Acute Disease; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D000069283:Rituximab / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D000069283:Rituximab
keywords: Chronic lymphocytic leukemia; Cytokine release syndrome; Leucémie lymphoïde chronique; Rituximab; Syndrome de relargage des cytokines; Thrombocytopenia; Thrombopénie